|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT01416311 |
|
Date of registration:
|
09/06/2011 |
|
Primary sponsor: |
|
|
Public title:
|
Drug Use Investigation for REVOLADE (ITP)
|
|
Scientific title:
|
Drug Use Investigation for REVOLADE (Chronic Idiopathic Thrombocytopenic Purpura) |
|
Date of first enrolment:
|
December 2010 |
|
Target sample size:
|
1000 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT01416311 |
|
Study type:
|
Observational |
|
Study design:
|
Time Perspective: Prospective
|
|
|
Contacts
|
|
Name:
|
GSK Clinical Trials |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
GlaxoSmithKline |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Subjects with chronic idiopathic thrombocytopenic purpura
Exclusion Criteria:
- Not applicable
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Chronic Idiopathic Thrombocytopenic Purpura
|
|
Intervention(s)
|
|
Drug: Eltrombopag
|
|
Primary Outcome(s)
|
|
The number of subjects with any adverse events treated with REVOLADE
[Time Frame: 1 year]
|
|
Secondary Outcome(s)
|
|
Appearance of thromboembolism
[Time Frame: 1 year]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|